[go: up one dir, main page]

AR049419A1 - Hidroxi-6-fenilfenantridinas sustituidas con heterociclilo - Google Patents

Hidroxi-6-fenilfenantridinas sustituidas con heterociclilo

Info

Publication number
AR049419A1
AR049419A1 ARP050100781A ARP050100781A AR049419A1 AR 049419 A1 AR049419 A1 AR 049419A1 AR P050100781 A ARP050100781 A AR P050100781A AR P050100781 A ARP050100781 A AR P050100781A AR 049419 A1 AR049419 A1 AR 049419A1
Authority
AR
Argentina
Prior art keywords
alkyl
alkoxy
completely
substituted
heterocyclic ring
Prior art date
Application number
ARP050100781A
Other languages
English (en)
Inventor
Ulrich Kautz
Beate Schmidt
Dieter Flockerzi
Armin Hatzelmann
Christof Zitt
Johannes Barsig
Degenhard Marx
Hans-Peter Kley
Original Assignee
Altana Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma Ag filed Critical Altana Pharma Ag
Publication of AR049419A1 publication Critical patent/AR049419A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D221/00Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04Ortho- or peri-condensed ring systems
    • C07D221/06Ring systems of three rings
    • C07D221/10Aza-phenanthrenes
    • C07D221/12Phenanthridines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D221/00Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04Ortho- or peri-condensed ring systems
    • C07D221/06Ring systems of three rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/473Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Reivindicacion 1: Compuestos de la formula (1) en la cual: R1 es hidroxilo, alcoxi C1-4, cicloalcoxi C3-7, cicloalquil C3-7-metoxi, 2,2-difluoroetoxi, o alcoxi C1-4 completamente o predominantemente sustituido con F; R2 es hidroxilo, alcoxi C1-4, cicloalcoxi C3-7, cicloalquil C3-7-metoxi, 2,2-difluoroetoxi, o alcoxi C1-4 completamente o predominantemente sustituido con F; o en la cual R1 y R2 juntos son un grupo alquilendioxi C1-2; R3 es H o alquilo C1-4; R31 es H o alquilo C1-4; y en una primera realizacion (realizacion a) de acuerdo con la presente, R4 es -O-R41, en donde R41 es H, alquilo C1-4, alcoxi C1-4-alquilo C1-4, hidroxialquilo C2-4, alquil C1-7-carbonilo o alquilo C1-4 completamente o predominantemente sustituido por F, y R5 es H o alquilo C1-4; o, en una segunda realizacion (realizacion b) de acuerdo con la presente, R4 es H o alquilo C1-4 y R5 es -O-R51, en donde R51 es H, alquilo C1-4, alcoxi C1-4-alquilo C1-4, hidroxialquilo C2-4, alquil C1-7-carbonilo o alquilo C1-4 completamente o predominantemente sustituido con F; R6 es H, halogeno, alquilo C1-4 o alcoxi C1-4; R7 es Het1, Het2, Har1, Het3 o Har2, en donde Het1 está sustituido opcionalmente con R71 y es un radical de anillo heterocíclico completamente saturado, de 3 a 7 miembros, monocíclico, que comprende uno a tres heteroátomos seleccionados independientemente del grupo que consiste de N, O y S, en donde R71 es alquilo C1-4, alcoxi C1-4 o alquilo C1-4 completamente o parcialmente sustituido con F; Het2 está opcionalmente sustituido con R72 y es un radical de anillo heterocíclico, saturado o insaturado, de 5 a 7 miembros, monocíclico, que comprende un átomo de N y opcionalmente uno o dos heteroátomos adicionales seleccionados independientemente del grupo que consiste de N, O y S y a cuyo anillo están ligados uno o dos sustituyentes oxo, en donde R72 es alquilo C1-4, alcoxi C1-4 o alquilo C1-4 completamente o parcialmente sustituido con F; Har1 está opcionalmente sustituido con R73 y es un radical de anillo heterocíclico completamente insaturado, de 5 miembros, monocíclico, que comprende uno a cuatro heteroátomos seleccionados independientemente del grupo que consiste de N, O y S, en donde R73 es alquilo C1- 4, alcoxi C1-4 o alquilo C1-4 completamente o parcialmente sustituido con F; Het3 está opcionalmente sustituido con R74 y es un radical de anillo heterocíclico parcialmente insaturado, de 5 o 6 miembros, monocíclico, que comprende un átomo de N y opcionalmente un heteroátomo adicional seleccionado del grupo que consiste de N, O y S, en donde R74 es alquilo C1-4, alcoxi C1-4 o alquilo C1-4 completamente o parcialmente sustituido con F; Har2 está opcionalmente sustituido con R75 y/o R76 y significa un radical de anillo heterocíclico completamente insaturado, de 6 miembros, monocíclico, que comprende uno a tres átomos de N, en donde R75 es alquilo C1-4, alcoxi C1-4, alquiltio C1-4, halogeno, hidroxilo, amino, mono- o dialquil C1-4- amino, o alquilo C1-4 completamente o parcialmente sustituido con F; R76 es alcoxi C1-4, alquiltio C1-4, hidroxilo, amino o mono- o dialquil C1-4-amino, y las sales, los N-oxidos y las sales de los N-oxidos de estos compuestos.
ARP050100781A 2004-03-03 2005-03-02 Hidroxi-6-fenilfenantridinas sustituidas con heterociclilo AR049419A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04005005 2004-03-03
EP04106372 2004-12-07

Publications (1)

Publication Number Publication Date
AR049419A1 true AR049419A1 (es) 2006-08-02

Family

ID=34961674

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050100781A AR049419A1 (es) 2004-03-03 2005-03-02 Hidroxi-6-fenilfenantridinas sustituidas con heterociclilo

Country Status (13)

Country Link
US (1) US20070191413A1 (es)
EP (1) EP1812400A1 (es)
JP (1) JP2007526284A (es)
KR (1) KR20060130684A (es)
AR (1) AR049419A1 (es)
AU (1) AU2005223370A1 (es)
BR (1) BRPI0508256A (es)
CA (1) CA2557730A1 (es)
IL (1) IL177301A0 (es)
NO (1) NO20064220L (es)
NZ (1) NZ549109A (es)
TW (1) TW200540157A (es)
WO (1) WO2005090311A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1539164B1 (en) * 2002-08-29 2006-12-20 ALTANA Pharma AG 2-hydroxy-6-phenylphenanthridines as pde-4 inhibitors
EP1536798B1 (en) 2002-08-29 2007-02-07 ALTANA Pharma AG 3-hydroxy-6-phenylphenanthridines as pde-4 inhibitors
CA2556086C (en) 2004-02-18 2014-04-01 Altana Pharma Ag Novel guanidinyl-substituted hydroxy-6-phenylphenenthridines as effective phosphodiesterase (pde) 4 inhibitors
CN104761545A (zh) 2004-03-03 2015-07-08 塔科达有限责任公司 新的羟基-6-杂芳基菲啶及其作为pde4抑制剂的用途
BRPI0508481A (pt) * 2004-03-10 2007-07-31 Altana Pharma Ag hidróxi-6-fenilenantridinas amido-substituìdas e seu uso como inibidores de pde4
NZ589278A (en) 2005-03-02 2012-04-27 Nycomed Gmbh Selected salts of 6-heterocyclyl substituted hexahydrophenanthridine derivatives
AU2008307195B2 (en) 2007-10-04 2012-11-22 F. Hoffmann-La Roche Ag Cyclopropyl aryl amide derivatives and uses thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1082959A1 (en) * 1991-09-20 2001-03-14 Glaxo Group Limited NK1 Antagonists for the treatment of depression
BR9707233A (pt) * 1996-01-31 1999-07-20 Byk Gulden Lomberg Chem Fab Fenantridinas
US6127378A (en) * 1996-03-26 2000-10-03 Byk Gulden Lomberg Chemische Fabrik Gmbh Phenanthridines substituted in the 6 position
CZ288752B6 (cs) * 1996-11-11 2001-08-15 Byk Gulden Lomberg Chemische Fabrik Gmbh Benzonaftyridinové deriváty a farmaceutický prostředek
DE69808099T2 (de) * 1997-07-25 2003-05-15 Altana Pharma Ag Substituierte 6-alkylphenanthridine
AU756349B2 (en) * 1997-07-25 2003-01-09 Altana Pharma Ag Substituted 6-phenylphenanthridines
ATE260899T1 (de) * 1997-07-25 2004-03-15 Altana Pharma Ag Neue tetrazolderivate
US6306869B1 (en) * 1998-05-05 2001-10-23 Byk Gulden Lomberg Chemische Febrik Gmbh N-oxides
CA2359449A1 (en) * 1999-01-15 2000-07-20 Beate Gutterer Phenanthridine-n-oxides with pde-iv inhibiting activity
DK1147089T3 (da) * 1999-01-15 2006-04-10 Altana Pharma Ag Phenylphenanthridiner med PDE-IV-inhiberende virkning
WO2000042017A1 (en) * 1999-01-15 2000-07-20 Byk Gulden Lomberg Chemische Fabrik Gmbh Phenanthridine-n-oxides with pde-iv inhibiting activity
DE60108758T2 (de) * 2000-07-14 2006-04-27 Altana Pharma Ag 6-heteroarylphenanthridine
DK1377574T3 (da) * 2001-02-21 2005-04-25 Altana Pharma Ag 6-phenylbenzonaphtyridiner
EP1537086A2 (en) * 2002-08-17 2005-06-08 ALTANA Pharma AG Novel phenanthridines
EP1536798B1 (en) * 2002-08-29 2007-02-07 ALTANA Pharma AG 3-hydroxy-6-phenylphenanthridines as pde-4 inhibitors
EP1539164B1 (en) * 2002-08-29 2006-12-20 ALTANA Pharma AG 2-hydroxy-6-phenylphenanthridines as pde-4 inhibitors
AU2003277069A1 (en) * 2002-09-30 2004-04-23 Ciphergen Biosystems, Inc. Apparatus and method for expression and capture of biomolecules and complexes on adsorbent surfaces
CA2556086C (en) * 2004-02-18 2014-04-01 Altana Pharma Ag Novel guanidinyl-substituted hydroxy-6-phenylphenenthridines as effective phosphodiesterase (pde) 4 inhibitors
JP2007527899A (ja) * 2004-03-09 2007-10-04 アルタナ ファルマ アクチエンゲゼルシャフト 新規のイソアミド置換されたヒドロキシ−6−フェニルフェナントリジン
JP2007527898A (ja) * 2004-03-10 2007-10-04 アルタナ ファルマ アクチエンゲゼルシャフト ジフルオロエトキシ置換された新規のヒドロキシ−6−フェニルフェナントリジン及びpde4インヒビターとしてのそれらの使用
BRPI0508481A (pt) * 2004-03-10 2007-07-31 Altana Pharma Ag hidróxi-6-fenilenantridinas amido-substituìdas e seu uso como inibidores de pde4
WO2005087744A1 (en) * 2004-03-10 2005-09-22 Altana Pharma Ag Novel thio-containing hydroxy-6-phenylphenanthridines and their use as pde4 inhibitors
JP2008528556A (ja) * 2005-02-01 2008-07-31 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規の6−ピリジルフェナントリジン
CA2598858A1 (en) * 2005-03-02 2006-09-08 Nycomed Gmbh 6 -heteroaryl-1, 2, 3,4,4a, 1ob-hexahydro-phenanthridines as pde-4 inhibitors for the treatment of inflammatory disorders
EP1858880A1 (en) * 2005-03-09 2007-11-28 Nycomed GmbH Amido-substituted 6-phenylphenanthridines
US20070154915A1 (en) * 2005-11-04 2007-07-05 Johji Inazawa Method for detecting cancer and a method for suppressing cancer

Also Published As

Publication number Publication date
KR20060130684A (ko) 2006-12-19
IL177301A0 (en) 2006-12-10
NO20064220L (no) 2006-09-18
WO2005090311A1 (en) 2005-09-29
BRPI0508256A (pt) 2007-07-31
NZ549109A (en) 2010-05-28
JP2007526284A (ja) 2007-09-13
CA2557730A1 (en) 2005-09-29
EP1812400A1 (en) 2007-08-01
US20070191413A1 (en) 2007-08-16
TW200540157A (en) 2005-12-16
WO2005090311A8 (en) 2006-10-26
AU2005223370A1 (en) 2005-09-29

Similar Documents

Publication Publication Date Title
PE20211698A1 (es) Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp
PE20220141A1 (es) Inhibidores de la proteina tirosina fosfatasa
CY1120899T1 (el) Παραγωγα 1,2,4-οξαδιαζολιου ως ανοσοτροποποιητες
AR119651A1 (es) Compuestos heterocíclicos y de heteroarilo para tratar la enfermedad de huntington
PE20240928A1 (es) Derivados de triazina y su uso en el tratamiento del cancer
PE20220567A1 (es) Nuevos derivados piperidinilo, un proceso para su preparacion y composiciones farmaceuticas que los contienen
ES2722409T3 (es) Moduladores de ROR gamma (RORy)
AR058896A1 (es) Isoxazolinas para controlar plagas de invertebrados
AR082914A1 (es) Heteroarilmetilamidas utiles para tratar enfermedades cardiovasculares y dislipemias, composiciones farmaceuticas que las contienen y proceso de preparacion de los mismos
ES2630079T3 (es) Moduladores de la ruta del complemento y usos de los mismos
CO6160315A2 (es) Agonistas de piridona del receptor acoplado a proteina g gpr119
PE20160501A1 (es) Derivados de quinolizina sustituidos utiles como inhibidores de integrasa del vih
AR091279A1 (es) Inhibidores macrociclicos de virus flaviviridae
AR043434A1 (es) Derivados de piperizacina acilados como agonistas del receptor de melanocortina-4. composiciones farmaceuticas y usos
CO6140056A2 (es) Compuestos amino -5-4(difluorometoxi)fenil sustituido-5-fenilimidazolona como inhibidores de beta -secretasa
AR077507A1 (es) Derivados de naftiridina-1-ona y composiciones farmaceuticas que los comprenden como inhibidores de cinasa syk
AR048427A1 (es) Derivados de sulfonilpirroles con actividad inhibitoria de la histona deacetilasa, composiciones farmaceuticas que los contienen y el uso de las mismas para el tratamiento de enfermedades relacionadas.
MX2015011131A (es) Composiciones, formulaciones y metodos para tratar enfermedades oculares.
AR061083A1 (es) Derivados de cicloalquilaminoacidos y composiciones farmaceuticas que los contienen
AR057703A1 (es) INHIBIDORES MACROCíCLICOS DEL VIRUS DE LA HEPATITIS C. PROCESO DE PREPARACIoN Y COMPOSICIONES FARMACÉUTICAS.
CO6220966A2 (es) Derivados de piridazinona utiles como inhibidores de glucano sintasa
AR089568A1 (es) Compuestos heterociclicos y sus metodos de usos
AR042833A1 (es) Derivados de pirrolopiridazina y procedimiento para su preparacion
ES2682398T3 (es) Derivados de 8-(piperazin-1-il)-1,2,3,4-tetrahidro-isoquinolina
ECSP088926A (es) Compuestos de piridil amida sustituidos como moduladores del receptor h3 de la histamina

Legal Events

Date Code Title Description
FB Suspension of granting procedure